ClinicalTrials.gg
RecruitingNCT06241144STELLAUpdated Apr 3, 2024

Supporting Lifestyle Changes After Delivery

An interventional study of Information and communication technology -based health behavior change support system in Obesity, Maternal and Lifestyle, sponsored by Oulu University Hospital. Recruiting at 1 site in Finland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Oulu University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Use of information and communication technology -based health behavior change support system in modifying lifestyle after delivery among women with obesity.

Read the detailed description

Postpartum weight retention is common and particular when accompanied with prior obesity, it further increases the risks of subsequent pregnancies and adverse effects on the long-term health.

The aim of this randomized controlled trial is to examine whether using an information and communication technology (ICT) -based health behavior change support system (HBCSS) reduce postpartum weight retention and disorders related to subsequent pregnancy. Web-based HBCSS application utilizes persuasive design and cognitive behavioral therapy.

200 participants with prepregnancy obesity (BMI ≥ 30.0 kg/m\^2) and age ≥ 18 years are randomly assigned into two groups after delivery in the Oulu university hospital. The study period begins 5-12 weeks after delivery. All participants will have conventional postpartum lifestyle counselling and the intervention group get in addition access for 12 months to web-based HBCSS application, which is recommended to use twice a week for 5-10 minutes.

Participants are followed by questionnaires up to 24 months. The main outcome is weight change from baseline to 12 and 24 months. Medical records and national registers are used for long-term follow-up. Researchers have permission to contact participants afterwards. The ethical approval is permitted by the Regional Medical Research Ethics Committee of the Wellbeing Services County of North Ostrobothnia. The authorization for the use of medical device is granted from the Finnish Medicines Agency. Recruitment of the participants will be performed 2/2024-1/2026.

02

Conditions studied

  • Obesity, Maternal
  • Lifestyle

Browse trials for

03

In context

Pregnancy in Obesity

60 studies on the registry are indexed under Pregnancy in Obesity; 17 are open to participants now.

This study's planned enrollment of 200 is above the median of 160 across 33 interventional studies indexed under Pregnancy in Obesity.

Browse Pregnancy in Obesity studies →

Lead sponsor

Oulu University Hospital is the lead sponsor of 40 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-pregnancy ≥ 30.0 kg/m\^2
  • Smartphone user

Exclusion criteria

Exclusion Criteria:

  • Eating disorder
  • Severe mental disorder
  • Use of other lifestyle support system or medication
  • Non-Finnish speaker
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intervention

    Device: Information and communication technology -based health behavior change support system

  • No intervention
    Control

Interventions

  • DeviceInformation and communication technology -based health behavior change support system

    Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education

06

What researchers measure

Primary outcomes

  1. Weight change

    Weight change in kilograms and change of body mass index (kg/m\^2)

    Time frame: 12 months

  2. Weight change

    Weight change in kilograms and change of body mass index (kg/m\^2)

    Time frame: 24 months

Secondary outcomes

  1. Weight change before subsequent pregnancy

    Weight change in kilograms and change of body mass index (kg/m\^2)

    Time frame: 1-8 years

  2. Pregnancy disorders in subsequent pregnancy (gestational diabetes, pre-eclampsia, gestational hypertension, preterm delivery)

    Number of participants with pregnancy disorders in subsequent pregnancy (gestational diabetes, pre-eclampsia, gestational hypertension, preterm delivery, mortality)

    Time frame: 1-8 years

  3. Neonatal outcome in subsequent pregnancy (preterm birth, large for gestational age, small for gestational age, need for neonatal intensive care, mortality)

    Number of neonates with adverse neonatal outcome (preterm birth, large for gestational age, small for gestational age, need for neonatal intensive care, mortality)

    Time frame: 1-8 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jan 2026, 23 months after the start.

Of 19 interventional studies with no phase under Pregnancy in Obesity, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 5, 2024
StartActual
Feb 9, 2024
Primary completionEst.
Jan 31, 2026
CompletionEst.
Dec 31, 2032
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06241144
Lead sponsor
Oulu University Hospital
Collaborators
University of Oulu
Responsible party
Marja Vääräsmäki (Professor, Oulu University Hospital) — Principal investigator
First posted
Feb 5, 2024
Start date
Feb 9, 2024
Primary completion
Jan 31, 2026 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Apr 3, 2024

Study contacts

Sanna Mustaniemi, PhD
Contact
sanna.mustaniemi@oulu.fi
+358 8669 9500
Elina Keikkala, PhD
Contact
elina.keikkala@oulu.fi
Marja Vääräsmäki, Professor
principal investigator · Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion